AUTHOR=Shui Lin , Cheng Ke , Li Xiaofen , Shui Pixian , Li Shuangshuang , Peng Yang , Li Jian , Guo Fengzhu , Yi Cheng , Cao Dan 

TITLE=Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma

JOURNAL=Frontiers in Immunology

VOLUME=Volume 11 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01127

DOI=10.3389/fimmu.2020.01127

ISSN=1664-3224

ABSTRACT=Abstract
Background: The efficacy of Immune checkpoint inhibitors (ICIs) monotherapy were proved to be disappointing in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence have shown that the promising efficacy of ICIs combined with systemic therapy in the first-line treatment in solid tumor.
Case presentation: We reported a case of metastatic PDAC patient who was detected with PD-L1 positive expression in liver tumors and had a long-term partial response and good tolerance to the combined approach of toripalimab (a novel PD-1 inhibitor) and gemcitabine plus nab-paclitaxel (GA). In addition, we described the phenomenon of pseudo-progression of this patients during the course of therapy.
Conclusion: For treatment-naïve metastatic PAC patients, GA plus toripalimab may provide a novel therapeutic approach with favorable response and manageable safety. Further clinical trials are needed to confirm the results. Pseudo-progression required specific attention and discrimination from true progression in patients undergoing immunotherapy.